Controlled-release hydromorphone and risk of infection in adults: a systematic review
Abstract Background Preliminary evidence suggests that people who inject drugs (PWID) may be at an increased risk of developing infective endocarditis (IE), hepatitis C virus (HCV) infection, and/or human immunodeficiency virus (HIV) infection from hydromorphone controlled-release formulation. The h...
Saved in:
Main Authors: | Andrea C. Tricco (Author), Amanda Parker (Author), Areej Hezam (Author), Vera Nincic (Author), Fatemeh Yazdi (Author), Yonda Lai (Author), Charmalee Harris (Author), Zachary Bouck (Author), Ahmed M. Bayoumi (Author), Sharon E. Straus (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A new extended release formulation (OROS®) of hydromorphone in the management of pain
by: Sharon M Weinstein
Published: (2008) -
Use of oral osmotic hydromorphone in opioid switch for cancer pain
by: Rosa Palomba, et al.
Published: (2008) -
Antitumor Effects of Hydromorphone on Human Gastric Cancer Cells in vitro
by: Liang B, et al.
Published: (2023) -
Hydromorphone Prescription for Pain in Children-What Place in Clinical Practice?
by: Frédérique Rodieux, et al.
Published: (2022) -
Antitumor Effects of Hydromorphone on Human Gastric Cancer Cells in vitro [Retraction]
by: Liang B, et al.
Published: (2024)